These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32786185)

  • 21. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
    Madden A; Hopwood M; Neale J; Treloar C
    PLoS One; 2018; 13(11):e0207226. PubMed ID: 30500863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of chronic hepatitis C in drug users: ethic, successful and useful].
    Remy AJ; Wenger H; Bouchkira H
    Presse Med; 2014 Dec; 43(12 Pt 1):1314-6. PubMed ID: 25307441
    [No Abstract]   [Full Text] [Related]  

  • 24. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
    Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
    J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment.
    Lewis H; Kunkel J; Axten D; Dalton J; Gardner H; Tippett A; Wynne S; Wilkinson M; Foster GR
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1258-63. PubMed ID: 27487966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Epidemiology of hepatitis C and vaccine perspectives].
    Nau JY
    Rev Med Suisse; 2016 Jan; 12(503):234-5. PubMed ID: 26939196
    [No Abstract]   [Full Text] [Related]  

  • 27. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
    Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
    BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HCV-infected patients need access now to new direct-acting antiviral agents to avert liver-related deaths.
    Sievert W; Razavi H; Thompson A; Zekry A; Dore GJ; Roberts SK
    Med J Aust; 2015 May; 202(9):479. PubMed ID: 25971570
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
    Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
    Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating intravenous drug users with hepatitis C infection: an opportunity in some settings.
    Chong VH; Jamaludin AZ; Jacob AP; Jalihal A
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1121. PubMed ID: 16957520
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug-drug interactions in the treatment of HCV among people who inject drugs.
    Mauss S; Klinker H
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S125-8. PubMed ID: 23884060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The end of hepatitis C.
    Sussman NL; Remien CH; Kanwal F
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):533-6. PubMed ID: 24480676
    [No Abstract]   [Full Text] [Related]  

  • 34. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
    Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review.
    Socías ME; Karamouzian M; Parent S; Barletta J; Bird K; Ti L
    Int J Drug Policy; 2019 Oct; 72():146-159. PubMed ID: 31147142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program.
    Stafford F; Dore GJ; Clackett S; Martinello M; Matthews GV; Grebely J; Balcomb AC; Hajarizadeh B
    Med J Aust; 2021 Oct; 215(7):332-333. PubMed ID: 34346057
    [No Abstract]   [Full Text] [Related]  

  • 37. Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?
    Makarenko I; Artenie A; Hoj S; Minoyan N; Jacka B; Zang G; Barlett G; Jutras-Aswad D; Martel-Laferriere V; Bruneau J
    Int J Drug Policy; 2019 Oct; 72():69-76. PubMed ID: 31010749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system.
    Butler K; Larney S; Day CA; Burns L
    Drug Alcohol Rev; 2019 Mar; 38(3):264-269. PubMed ID: 30548702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
    Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
    J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients.
    Rivero-Juarez A; Tellez F; Castaño-Carracedo M; Merino D; Espinosa N; Santos J; Macias J; Paniagua-García M; Zapata-Lopez A; Collado A; Gómez-Vidal MA; Perez-Stachowski J; Muñoz-Medina L; Fernandez-Fuertes E; Rivero A;
    HIV Med; 2019 Jul; 20(6):359-367. PubMed ID: 31006980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.